Melissa Wilson
YOU?
Author Swipe
View article: Sex-specific placental transcriptome alterations in late-onset preeclampsia reveal male-biased immune and metabolic dysregulation
Sex-specific placental transcriptome alterations in late-onset preeclampsia reveal male-biased immune and metabolic dysregulation Open
Background Preeclampsia is a hypertensive disorder of pregnancy with major maternal and fetal consequences. While the molecular basis of early-onset preeclampsia is well studied, the mechanisms underlying late-onset disease—and how they di…
View article: Immunoediting restricts clonal neoantigens in primary human tumors 2606
Immunoediting restricts clonal neoantigens in primary human tumors 2606 Open
Description Evidence consistent with immunoediting in human cancer has been identified through associative studies. To provide direct evidence that differences in the neoantigen profile are immune-mediated, we compared the neoantigen profi…
View article: Structural changes from wild-type define tumor-rejecting neoantigens
Structural changes from wild-type define tumor-rejecting neoantigens Open
Background Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). O…
View article: SAT-454 Visual Hallucination, an Unusual Presentation in Immunotherapy Induced Adrenal Insufficiency - A Case Study
SAT-454 Visual Hallucination, an Unusual Presentation in Immunotherapy Induced Adrenal Insufficiency - A Case Study Open
Disclosure: U.B. Zakia: None. M. Aiad: None. G. Smith: None. M. Wilson: None. Background: Adrenal insufficiency (AI) is a significant endocrine toxicity caused by immunotherapy (3,4). Immune checkpoint inhibitors may result in primary (n=1…
View article: Genome Report: <i>De novo</i> genome assembly of the greater Bermuda land snail, <i>Poecilozonites bermudensis</i> (Mollusca: Gastropoda), confirms ancestral genome duplication
Genome Report: <i>De novo</i> genome assembly of the greater Bermuda land snail, <i>Poecilozonites bermudensis</i> (Mollusca: Gastropoda), confirms ancestral genome duplication Open
Poecilozonites bermudensis , the greater Bermuda land snail, is a critically endangered species and one of only two extant members in its genus. These snails are one of Bermuda’s few endemic animal clades and their rich fossil record was t…
View article: A threshold level of JNK activates damage-responsive enhancers via JAK/STAT to promote tissue regeneration
A threshold level of JNK activates damage-responsive enhancers via JAK/STAT to promote tissue regeneration Open
Tissue regeneration requires precise activation and coordination of genes, many of which are reused from development. Although key factors have been identified, how their expression is initiated and spatially regulated after injury remains…
View article: Predictive Modelling of nephrotoxicity from vancomycin and piperacillin-tazobactam (VPT) combination and vancomycin as monotherapy: an artificial intelligence (AI) Approach
Predictive Modelling of nephrotoxicity from vancomycin and piperacillin-tazobactam (VPT) combination and vancomycin as monotherapy: an artificial intelligence (AI) Approach Open
Introduction: The concomitant use of vancomycin with β-lactam antibiotics, such as piperacillin-tazobactam, presents a clinical challenge due to the heightened risk of acute kidney injury (AKI). This study aims to develop a predictive mode…
View article: A threshold level of JNK activates damage-responsive enhancers via JAK/STAT to promote tissue regeneration
A threshold level of JNK activates damage-responsive enhancers via JAK/STAT to promote tissue regeneration Open
Tissue regeneration requires precise activation and coordination of genes, many of which are reused from development. While key factors have been identified, how their expression is initiated and spatially regulated after injury remains un…
View article: NCOG-12. TREATMENT AND MORTALITY OF PRIMARY BRAIN TUMORS: A SINGLE CENTER OBSERVATIONAL STUDY OF GLIOBLASTOMAS AND ASTROCYTOMAS
NCOG-12. TREATMENT AND MORTALITY OF PRIMARY BRAIN TUMORS: A SINGLE CENTER OBSERVATIONAL STUDY OF GLIOBLASTOMAS AND ASTROCYTOMAS Open
Glioblastoma multiforme (GBM) is a WHO grade IV malignant tumor with a relatively poor prognosis (median survival of 15 months). Astrocytomas are WHO grade I-III tumors with a better prognosis than GBM; their median survival ranging from 2…
View article: Inherited Basaloid Neoplasms Associated With <i>SUFU</i> Pathogenic Variants
Inherited Basaloid Neoplasms Associated With <i>SUFU</i> Pathogenic Variants Open
Importance Germline SUFU pathogenic variants (PVs) have previously been associated with basal cell nevus syndrome (BCNS) and multiple infundibulocystic basal cell carcinoma syndrome; however, a broader spectrum of cutaneous findings in pat…
View article: Distinct sets of molecular characteristics define tumor-rejecting neoantigens
Distinct sets of molecular characteristics define tumor-rejecting neoantigens Open
Challenges in identifying tumor-rejecting neoantigens limit the efficacy of neoantigen vaccines to treat cancers, including cutaneous squamous cell carcinoma (cSCC). A minority of human cSCC tumors shared neoantigens, supporting the need f…
View article: 136 Neoantigen-specific CD8 T cell responses constrain cutaneous squamous cell carcinoma
136 Neoantigen-specific CD8 T cell responses constrain cutaneous squamous cell carcinoma Open
Background Non-melanoma skin cancer, which includes cutaneous squamous cell carcinoma (cSCC), is the most common cancer. In the US, there are more than a million cases of cSCC diagnosed annually. Although most early stage cSCC are successf…
View article: 137 Majority of mutations in cutaneous squamous cell carcinoma are unique to individual tumors
137 Majority of mutations in cutaneous squamous cell carcinoma are unique to individual tumors Open
Background Determining the shared and unique neoantigen profiles in cutaneous squamous cell carcinoma (cSCC) is critical to selecting immunotherapeutic approaches for improved prevention and treatment of cSCC. Nonmelanoma skin cancer, incl…
View article: Table S1 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Table S1 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Plasma sulforaphane concentrations by day, dose, and pre- or post-BSE-SFN administration
View article: Table S2 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Table S2 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Skin sulforaphane concentration post-BSE-SFN administration by dose group and day
View article: Table S2 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Table S2 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Skin sulforaphane concentration post-BSE-SFN administration by dose group and day
View article: Table S1 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Table S1 from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Plasma sulforaphane concentrations by day, dose, and pre- or post-BSE-SFN administration
View article: Data from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Data from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation–induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN at three dosage…
View article: Data from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi
Data from Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Open
Broccoli sprout extract containing sulforaphane (BSE-SFN) has been shown to inhibit ultraviolet radiation–induced damage and tumor progression in skin. This study evaluated the toxicity and potential effects of oral BSE-SFN at three dosage…
View article: Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2 Open
PURPOSE NCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, a MEK1/2 inhibitor, in p…
View article: Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia
Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia Open
Asciminib, a “Specifically Targeting the ABL Myristoyl Pocket” inhibitor, is a new drug in the treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML). Hemocytopenias associated with asciminib are common adver…
View article: Supplementary Figure S5 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Supplementary Figure S5 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma Open
Kaplan-Meier analysis shows no significant difference in overall survival of melanoma patients from the validation cohort based on KDR status (TA,AA: Q472H variant, TT: WT variant).
View article: Supplementary Figure S2 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Supplementary Figure S2 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma Open
Somatic mutations (top column) identified by Ion Torrent sequencing of the pilot melanoma cohort are listed for each patient (left hand column).
View article: supplemental tables 1-5 and figure legends from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
supplemental tables 1-5 and figure legends from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Open
Supplemental Table 1: Genes analyzed which are known to be involved in melanoma pathogenesis Supplemental Table 2: Patient demographics and disease characteristics Supplemental Table 3: Clinical outcomes Supplemental Table 4: BRAF gene amp…
View article: Supplement Figure 3 from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Supplement Figure 3 from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Open
Supplemental Figure 3. BRAF and MET gene amplifications are associated with BRAF V600K mutation cohort
View article: Supplementary Figure S4 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Supplementary Figure S4 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma Open
Clinically relevant somatic mutations identified in WT melanoma patients in the pilot cohort
View article: Data from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Data from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Open
Purpose: Copy number alterations have been shown to be involved in melanoma pathogenesis. The randomized phase III clinical trial E2603: carboplatin, paclitaxel, ± sorafenib (CP vs. CPS) offers a large collection of tumor samples to evalua…
View article: Data from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Data from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Open
Purpose: Copy number alterations have been shown to be involved in melanoma pathogenesis. The randomized phase III clinical trial E2603: carboplatin, paclitaxel, ± sorafenib (CP vs. CPS) offers a large collection of tumor samples to evalua…